PharmaGap, Inc. (PHRGF.PK) In-Vitro Testing Shows Significant Reduction in Melanoma Cancer Cell Growth
Biotechnology company PharmaGap Inc. today announced 80 percent average growth inhibition in in-vitro trials of its lead cancer drug GAP-107B8 in melanoma testing at Memorial Sloan-Kettering Cancer Center (MSKCC). GAP-107B8 studies have demonstrated the drug as highly cytotoxic to numerous cancer types, including chemo-resistant cancers, in vitro. PharmaGap said its test program at MSKCC will proceed to animal tests, with results expected during the third quarter. Animal testing will allow the company to research and identify various possibilities for the drug. "We are seeing promising results in the melanoma cell line panel, and I am excited to be continuing with…